CSIMarket
 


Geovax Labs Inc   (GOVX)
Other Ticker:  
 

Geovax Labs Inc 's Working Capital Ratio

GOVX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 2.09 below Geovax Labs Inc average.

Within Major Pharmaceutical Preparations industry 285 other companies have achieved higher Working Capital Ratio than Geovax Labs Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1027 to 1597.

Explain Working Capital Ratio
How much in Current Assets GOVX´s has?
What is the value of GOVX´s Current Liabilities?


GOVX Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 47.86 % 21.31 % 29.65 % -12.65 % 1326.69 %
Y / Y Current Assets Change -59.04 % -38.11 % 56.11 % 148.61 % 98.87 %
Working Capital Ratio MRQ 2.09 4.85 5.73 6.1 7.55
GOVX's Total Ranking # 1597 # 1027 # 906 # 837 # 673
Seq. Current Liabilities Change 73.34 % -9.99 % -4.4 % -0.87 % 42.21 %
Seq. Current Assets Change -25.35 % -23.71 % -10.19 % -19.92 % 12.79 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 286
Healthcare Sector # 558
Overall Market # 1597


Working Capital Ratio Statistics
High Average Low
54.78 8.26 0.2
(Jun 30 2021)   (Jun 30 2019)




Financial Statements
Geovax Labs Inc 's Current Liabilities $ 7 Millions Visit GOVX's Balance sheet
Geovax Labs Inc 's Current Assets $ 15 Millions Visit GOVX's Balance sheet
Source of GOVX's Sales Visit GOVX's Sales by Geography


Cumulative Geovax Labs Inc 's Working Capital Ratio

GOVX's Working Capital Ratio for the trailling 12 Months

GOVX Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 47.86 % 21.31 % 29.65 % -12.65 % 1326.69 %
Y / Y Current Assets TTM Growth -59.04 % -38.11 % 56.11 % 148.61 % 98.87 %
Working Capital Ratio TTM 4.38 6.11 7.06 6.93 5.64
Total Ranking TTM # 2366 # 518 # 678 # 3809 # 772
Seq. Current Liabilities TTM Growth 73.34 % -9.99 % -4.4 % -0.87 % 42.21 %
Seq. Current Assets TTM Growth -25.35 % -23.71 % -10.19 % -19.92 % 12.79 %


On the trailing twelve months basis Due to jump in Current Liabilities in the III Quarter 2023 to $7.08 millions, cumulative Working Capital Ratio decreased to 4.38 below the Geovax Labs Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 282 other companies have achieved higher Working Capital Ratio than Geovax Labs Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 518 to 2366.

Explain Working Capital Ratio
How much in Current Assets GOVX´s has?
What is the value of GOVX´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 283
Healthcare Sector # 608
Within the Market # 2366


trailing twelve months Working Capital Ratio Statistics
High Average Low
35.28 5.5 0.29
(Sep 30 2021)   (Dec 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Unity Biotechnology Inc   5.74 $ 49.538  Millions$ 8.633  Millions
Sarepta Therapeutics Inc   5.72 $ 2,450.849  Millions$ 428.249  Millions
Immunogen inc   5.70 $ 766.900  Millions$ 134.660  Millions
Macrogenics Inc   5.68 $ 291.319  Millions$ 51.291  Millions
Dyne Therapeutics Inc   5.67 $ 168.216  Millions$ 29.692  Millions
Alx Oncology Holdings Inc  5.66 $ 199.071  Millions$ 35.142  Millions
Clearside Biomedical Inc   5.63 $ 30.815  Millions$ 5.473  Millions
Kala Bio inc   5.62 $ 57.902  Millions$ 10.301  Millions
Repare Therapeutics Inc   5.62 $ 275.093  Millions$ 48.972  Millions
Ardelyx Inc   5.54 $ 241.216  Millions$ 43.529  Millions
Bridgebio Pharma Inc   5.54 $ 587.670  Millions$ 106.065  Millions
Neurobo Pharmaceuticals Inc   5.54 $ 26.145  Millions$ 4.722  Millions
Tg Therapeutics Inc   5.53 $ 319.114  Millions$ 57.678  Millions
Bellerophon Therapeutics inc  5.41 $ 4.979  Millions$ 0.920  Millions
Calcimedica Inc   5.40 $ 15.273  Millions$ 2.826  Millions
Salarius Pharmaceuticals inc   5.38 $ 8.324  Millions$ 1.548  Millions
Annovis Bio inc   5.31 $ 10.223  Millions$ 1.926  Millions
Y mabs Therapeutics inc   5.27 $ 114.860  Millions$ 21.812  Millions
Pulmatrix Inc   5.24 $ 23.229  Millions$ 4.429  Millions
Schrodinger Inc   5.21 $ 547.761  Millions$ 105.038  Millions
Mirum Pharmaceuticals Inc   5.20 $ 388.579  Millions$ 74.664  Millions
Frequency Therapeutics Inc   5.19 $ 42.500  Millions$ 8.185  Millions
Legend Biotech Corporation  5.19 $ 1,497.799  Millions$ 288.531  Millions
Zymeworks Inc   5.14 $ 374.634  Millions$ 72.847  Millions
Foghorn Therapeutics Inc   5.10 $ 265.442  Millions$ 52.012  Millions
Sunshine Biopharma Inc   5.00 $ 25.435  Millions$ 5.088  Millions
Biohaven Ltd   4.99 $ 310.570  Millions$ 62.177  Millions
Context Therapeutics Inc   4.99 $ 22.971  Millions$ 4.604  Millions
Travere Therapeutics Inc   4.92 $ 686.230  Millions$ 139.433  Millions
United Therapeutics Corporation  4.92 $ 3,458.900  Millions$ 703.500  Millions

Date modified: 2024-02-27T10:03:31+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com